Finance

Lists
Why is ZNTL down 2,16%?
Dive Deeper
ZNTL:NASDAQ
Zentalis Pharmaceuticals Inc
2,72 USD
-2,16%
(-0,060) 1D
6-окт., 14:58:30 GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for ZNTL...
Open
2,81 USD
High
2,82 USD
Low
2,65 USD
Mkt. cap
233,42 млн
Avg. vol.
1,18 млн
Volume
564,68 миң
52-wk high
6,95 USD
52-wk low
1,21 USD
EPS
-1,96 USD
Beta
1,93
Shares outstanding
94,67 млн
No. of employees
106
Open
2,81 USD
High
2,82 USD
Low
2,65 USD
Mkt. cap
233,42 млн
Avg. vol.
1,18 млн
Volume
564,68 миң
52-wk high
6,95 USD
52-wk low
1,21 USD
EPS
-1,96 USD
Beta
1,93
Shares outstanding
94,67 млн
No. of employees
106
News stories
From web sources and news partners
About Zentalis Pharmaceuticals Inc
CEO-
Employees106
Founded2014
Headquarters-
Sector-
Websitezentalis.com
Analyst ratings
Based on 8 analysts giving stock ratings to ZNTL in the past 3 months
Strong buy
Buy
6
Hold
2
Sell
0
12-month forecast
Based on 8 Wall Street analysts offering 12 month price targets for ZNTL in the last 3 months.
Highest
Current 2,72 USD
11,00 USD (+304,41%)
Average
8,14 USD (+199,26%)
Lowest
5,00 USD (+83,82%)
Analyst
Recommendation
Action
Price target
Projected
Date
Unknown Analyst
Leerink Partners
Buy
Upgraded
8,00 USD
+194,1%
10/05/2026
Yanan Zhu
Wells Fargo
Hold
Maintained
5,00 USD
+83,8%
09/29/2026
Matt Phipps
William Blair
Buy
Initiated
-
-
09/15/2026
Graig Suvannavejh
Mizuho Securities
Buy
Reiterated
8,00 USD
+194,1%
08/11/2026
Michael Ulz
Morgan Stanley
Hold
Maintained
5,00 USD
+83,8%
08/07/2026
Andres Y. Maldonado
H.C. Wainwright
Buy
Maintained
10,00 USD
+267,6%
08/07/2026
Michael Schmidt
Guggenheim
Buy
Maintained
10,00 USD
+267,6%
08/07/2026
Michael King
Rodman & Renshaw
Buy
Initiated
11,00 USD
+304,4%
07/23/2026
Jay Olson
Oppenheimer
Buy
Initiated
9,00 USD
+230,9%
06/15/2026
Unknown Analyst
Wedbush
Hold
Maintained
4,00 USD
+47,1%
05/13/2026
Matthew Biegler
Oppenheimer
Buy
Reiterated
9,00 USD
+230,9%
05/13/2026
Eva Fortea Verdejo
Wells Fargo
Hold
Reiterated
5,00 USD
+83,8%
05/13/2026
Tyler Van Buren
TD Cowen
Buy
Maintained
-
-
05/12/2026
Previous reportsAll values in USD
Loading Previous Earnings...
Revenue
Net income
All values in USD
2025-ж. сен.
2025-ж. дек.
2026-ж. мар.
2026-ж. июн.
Revenue
-
-
-
-
Cost of goods sold
-
-
-
-
Cost of revenue
-
-
-
-
Research and development expenses
22,95 млн
30,69 млн
28,72 млн
35,16 млн
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
10,78 млн
3,77 млн
9,14 млн
9,23 млн
Operating expense
33,73 млн
34,46 млн
37,86 млн
44,39 млн
Total operating expenses
33,73 млн
34,46 млн
37,86 млн
44,39 млн
Operating income
-33,73 млн
-34,46 млн
-37,86 млн
-44,39 млн
Other non operating income
-
-
-
-
EBT including unusual items
-26,69 млн
-34,77 млн
-35,23 млн
-42,15 млн
EBT excluding unusual items
-26,69 млн
-34,12 млн
-35,23 млн
-42,15 млн
Income tax expense
-
442,00 миң
120,00 миң
138,00 миң
Effective tax rate
-
-1,27%
-0,34%
-0,33%
Other operating expenses
-
-
-
-
Net income
-26,69 млн
-35,22 млн
-35,35 млн
-42,29 млн
Net profit margin
-
-
-
-
Earnings per share
-0,37
-0,49
-0,50
-0,59
Interest and investment income
7,04 млн
338,00 миң
2,62 млн
2,24 млн
Interest expense
-
-
-
-
Net interest expenses
7,04 млн
338,00 миң
2,62 млн
2,24 млн
Depreciation and amortization charges
-
-
-
-
EBITDA
-33,57 млн
-34,30 млн
-37,70 млн
-44,24 млн
Gain or loss from assets sale
-103,00 миң
-26,00 миң
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
Google колдонмолору